APLLTD NSI Week ended 07 Aug 2026

Weekly Investor Report

Alembic Pharmaceuticals Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 830.1 INR
4.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 9.7% above the Trend Line and sits at 53.1% of its 52-week range. The latest completed week returned 4.1%, after a 0.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100.

Setup score 55 out of 100
Latest Close 830.1 INR 7 Aug 2026
1W Return 4.1% latest completed week
4W Return 0.6% short-term follow-through
12W Return 5.9% quarterly tape
Trend Breadth 19.2% 10 of 52 weeks active
Volume Ratio 2.6x vs 13-week average
What is working
  • The trend backdrop is active with a 3-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.1% Latest completed week; four-week move 0.6%. Indicator stack 21/69 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 29 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 9.7% above the Trend Line and sits at 53.1% of its 52-week range. The latest completed week returned 4.1%, after a 0.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4412-week average 0.28

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.44Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.6% over four weeks, 5.9% over 12 weeks, and -11.3% over one year. The current trend has remained active for 3 consecutive weeks.

Performance by holding period

1W4.1%
4W0.6%
12W5.9%
26W4.1%
52W-11.3%
Active trend streak3 weeks
Active weeks in one year10
Trend breadth19.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.02Latest activity-pressure read.
Pressure change7.9%Four-week change in activity pressure.
Leadership1.94Latest relative-leadership reading.
RS change40.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 88%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength72/100Blend of value, momentum, and quality. Underlying universe rank 29; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality79/100Profitability and accounting quality. Underlying universe rank 22; rank 1 is best.
Momentum29/100Medium-term price momentum. Underlying universe rank 72; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework43/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
25.2x
Price divided by trailing earnings.
Price / sales
2.3x
Market value relative to trailing revenue.
EV / EBITDA
16.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
1.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
72.3%
Gross profit retained from each unit of revenue.
Operating margin
10.6%
Operating profit retained from revenue.
Free-cash-flow margin
4.0%
Free cash flow generated from revenue.
Return on invested capital
8.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
10.3%
Latest one-year revenue growth.
EPS growth
15.7%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
1.4%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
1.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 29 relevant articles.

3 positive · 25 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-17.2%Distance below the 52-week high.
13-week volatility2.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+10.4%Week of 10 Apr.
Worst week-6.8%Week of 27 Feb.
Latest week+4.1%Week of 7 Aug.

Shape of recent returns

Strong gains5
Modest gains6
Flat weeks0
Modest losses12
Sharp losses3
Recent vol2.9%13-week weekly-return volatility.
Base vol3.3%52-week weekly-return volatility.
Up/down split21/30Count of positive and negative weeks in the 52-week window.
Average skew2.8% / -2.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape52/100

Trend, activity pressure, participation, and risk combine to a 52/100 tape read.

 Indicator analysis47/100

Latest 12-week confirmation: trend 3/12, activity pressure 12/12, relative leadership 2/12.

Activity pressure 0.44; No reversal markers Factors62/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 23; Small Cap Core rank 41 SVQF43/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 900.5 of 1576 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 29 relevant articles.

Read This Before Considering Alembic Pharmaceuticals Limited (NSE:APLLTD) For Its Upcoming ₹12.00 Dividend Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026830.1 INR4.1%756.8 INR895.5 INR1.021.941.2MOn
31 Jul 2026797.0 INR1.4%755.8 INR895.1 INR1.03-1.63296.8KOn
24 Jul 2026785.9 INR-3.3%757.1 INR894.9 INR1.09-0.86284.6KOn
17 Jul 2026813.0 INR-1.5%759.3 INR894.7 INR1.12-0.21595.1KOff
10 Jul 2026825.1 INR1.7%760.8 INR893.8 INR0.951.38629.6KOff
3 Jul 2026811.6 INR6.8%762.5 INR892.6 INR0.70-0.79143.2KOff
26 Jun 2026760.2 INR-0.4%765.5 INR891.5 INR0.54-6.540Off
19 Jun 2026763.0 INR2.6%770.4 INR890.5 INR0.50-6.33279.3KOff
12 Jun 2026743.3 INR0.7%775.0 INR889.4 INR0.56-7.5086.2KOff
5 Jun 2026738.4 INR0.3%780.3 INR888.4 INR0.73-7.5598.1KOff
29 May 2026736.1 INR-2.6%786.5 INR887.4 INR0.93-8.93408.5KOff
22 May 2026755.7 INR-3.6%791.8 INR886.1 INR0.99-7.67908.6KOff
15 May 2026784.1 INR-0.4%797.5 INR884.6 INR0.91-4.26894.7KOff
8 May 2026787.0 INR4.2%802.6 INR883.0 INR0.82-6.171.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context